Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity
- 24 August 2011
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 3 (97), 97ra81
- https://doi.org/10.1126/scitranslmed.3002473
Abstract
A high-throughput screen for transthyretin ligands that inhibit protein aggregation identifies agents that prevent amyloid formation and toxicity toward cardiomyocytes.Keywords
This publication has 52 references indexed in Scilit:
- Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogsBiochemical and Biophysical Research Communications, 2011
- Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) StudiesAmerican Heart Journal, 2010
- Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidosesCurrent Opinion in Structural Biology, 2010
- Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosisAmerican Heart Journal, 2009
- Toward Optimization of the Linker Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural StudiesJournal of Medicinal Chemistry, 2008
- Heart Transplantation for Homozygous Familial Transthyretin (TTR) V122I Cardiac AmyloidosisAmerican Journal of Transplantation, 2008
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsBMJ, 2006
- Native State Kinetic Stabilization as a Strategy To Ameliorate Protein Misfolding Diseases: A Focus on the Transthyretin AmyloidosesAccounts of Chemical Research, 2005
- Folding proteins in fatal waysNature, 2003
- Therapeutic approaches to protein-misfolding diseasesNature, 2003